| 2.28 -0.13 (-5.39%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.4 |
1-year : | 3.92 |
| Resists | First : | 2.91 |
Second : | 3.35 |
| Pivot price | 2.51 |
|||
| Supports | First : | 2.2 | Second : | 1.83 |
| MAs | MA(5) : | 2.33 |
MA(20) : | 2.58 |
| MA(100) : | 3.2 |
MA(250) : | 3.95 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 17  |
D(3) : | 10.8 |
| RSI | RSI(14): 33.3 |
|||
| 52-week | High : | 8.21 | Low : | 2.2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CTMX ] has closed above bottom band by 11.2%. Bollinger Bands are 22.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.44 - 2.46 | 2.46 - 2.47 |
| Low: | 2.22 - 2.24 | 2.24 - 2.25 |
| Close: | 2.25 - 2.28 | 2.28 - 2.3 |
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
Fri, 16 Oct 2026
CEO exercised options and sold 101,793 CytomX Therapeutics (CTMX) shares under a trading plan. - Stock Titan
Thu, 10 Sep 2026
CytomX Therapeutics, Inc. (CTMX) Presents at Wells Fargo 21st Annual Healthcare Conference - Slideshow - Seeking Alpha
Tue, 01 Sep 2026
CytomX Therapeutics to Present at Upcoming September Investor Conferences - Stock Titan
Fri, 07 Aug 2026
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ... - Yahoo Finance
Thu, 30 Jul 2026
CytomX's second-quarter results call is set for Aug. 6 at 5 p.m. ET - Stock Titan
Mon, 27 Jul 2026
More Than Three Decades in Oncology: Fuchs Joins CytomX Board - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 218 (M) |
| Held by Insiders | 1.7966e+008 (%) |
| Held by Institutions | 0.5 (%) |
| Shares Short | 33,510 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.621e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 677 % |
| Return on Equity (ttm) | -19.6 % |
| Qtrly Rev. Growth | 1.83e+007 % |
| Gross Profit (p.s.) | -42 |
| Sales Per Share | -17.16 |
| EBITDA (p.s.) | 8.31818e+006 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -82 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.14 |
| Price to Cash Flow | 3.6 |
| Dividend | 0 |
| Forward Dividend | 4.081e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|